CTMX Reports $76.2M Revenue, $137.1M Cash, Positive Varseta-M CRC Data, FDA Target Mid‑2026, CX‑801 Combination 2026
CytomX Therapeutics, Inc. · PHARMACEUTICAL PREPARATIONS · Now $3.45
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS